Should every patient with pancreatic cancer receive perioperative/neoadjuvant therapy?
Pancreatic ductal adenocarcinoma is a highly aggressive disease, and medical as well as surgical therapeutic options are limited. This article reviews stage dependent treatment options, with a special focus on the current controversy of perioperative treatment regimens in initially borderline resect...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Thieme Medical and Scientific Publishers Pvt. Ltd.
2016-01-01
|
| Series: | Indian Journal of Medical and Paediatric Oncology |
| Subjects: | |
| Online Access: | http://www.ijmpo.org/article.asp?issn=0971-5851;year=2016;volume=37;issue=4;spage=211;epage=213;aulast=Nitsche |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850177391337406464 |
|---|---|
| author | Ulrich Nitsche Bo Kong Alexander Balmert Helmut Friess Jörg Kleeff |
| author_facet | Ulrich Nitsche Bo Kong Alexander Balmert Helmut Friess Jörg Kleeff |
| author_sort | Ulrich Nitsche |
| collection | DOAJ |
| description | Pancreatic ductal adenocarcinoma is a highly aggressive disease, and medical as well as surgical therapeutic options are limited. This article reviews stage dependent treatment options, with a special focus on the current controversy of perioperative treatment regimens in initially borderline resectable or locally advanced patients. Neoadjuvant treatment can potentially increase the rate of complete tumor resection and may be more effective than adjuvant systemic therapy. Further, in the case of disease progression during or after neoadjuvant therapy, patients can be spared extensive surgery. Today, common therapeutic regimens include gemcitabine/nab-paclitaxel and FOLFIRINOX, as well as chemoradiation. However, because of the paucity of evidence from randomized trials, most guidelines do not recommend neoadjuvant therapy in resectable tumors, and for borderline or locally advanced tumors only within clinical trials. Importantly, every patient should be discussed in multidisciplinary tumor boards. |
| format | Article |
| id | doaj-art-bee280fb122b49549a7ad1ae6c880aee |
| institution | OA Journals |
| issn | 0971-5851 |
| language | English |
| publishDate | 2016-01-01 |
| publisher | Thieme Medical and Scientific Publishers Pvt. Ltd. |
| record_format | Article |
| series | Indian Journal of Medical and Paediatric Oncology |
| spelling | doaj-art-bee280fb122b49549a7ad1ae6c880aee2025-08-20T02:18:58ZengThieme Medical and Scientific Publishers Pvt. Ltd.Indian Journal of Medical and Paediatric Oncology0971-58512016-01-0137421121310.4103/0971-5851.195731Should every patient with pancreatic cancer receive perioperative/neoadjuvant therapy?Ulrich NitscheBo KongAlexander BalmertHelmut FriessJörg KleeffPancreatic ductal adenocarcinoma is a highly aggressive disease, and medical as well as surgical therapeutic options are limited. This article reviews stage dependent treatment options, with a special focus on the current controversy of perioperative treatment regimens in initially borderline resectable or locally advanced patients. Neoadjuvant treatment can potentially increase the rate of complete tumor resection and may be more effective than adjuvant systemic therapy. Further, in the case of disease progression during or after neoadjuvant therapy, patients can be spared extensive surgery. Today, common therapeutic regimens include gemcitabine/nab-paclitaxel and FOLFIRINOX, as well as chemoradiation. However, because of the paucity of evidence from randomized trials, most guidelines do not recommend neoadjuvant therapy in resectable tumors, and for borderline or locally advanced tumors only within clinical trials. Importantly, every patient should be discussed in multidisciplinary tumor boards.http://www.ijmpo.org/article.asp?issn=0971-5851;year=2016;volume=37;issue=4;spage=211;epage=213;aulast=NitscheNeoadjuvantpancreatic cancerpancreatic ductal adenocarcinomaperioperative |
| spellingShingle | Ulrich Nitsche Bo Kong Alexander Balmert Helmut Friess Jörg Kleeff Should every patient with pancreatic cancer receive perioperative/neoadjuvant therapy? Indian Journal of Medical and Paediatric Oncology Neoadjuvant pancreatic cancer pancreatic ductal adenocarcinoma perioperative |
| title | Should every patient with pancreatic cancer receive perioperative/neoadjuvant therapy? |
| title_full | Should every patient with pancreatic cancer receive perioperative/neoadjuvant therapy? |
| title_fullStr | Should every patient with pancreatic cancer receive perioperative/neoadjuvant therapy? |
| title_full_unstemmed | Should every patient with pancreatic cancer receive perioperative/neoadjuvant therapy? |
| title_short | Should every patient with pancreatic cancer receive perioperative/neoadjuvant therapy? |
| title_sort | should every patient with pancreatic cancer receive perioperative neoadjuvant therapy |
| topic | Neoadjuvant pancreatic cancer pancreatic ductal adenocarcinoma perioperative |
| url | http://www.ijmpo.org/article.asp?issn=0971-5851;year=2016;volume=37;issue=4;spage=211;epage=213;aulast=Nitsche |
| work_keys_str_mv | AT ulrichnitsche shouldeverypatientwithpancreaticcancerreceiveperioperativeneoadjuvanttherapy AT bokong shouldeverypatientwithpancreaticcancerreceiveperioperativeneoadjuvanttherapy AT alexanderbalmert shouldeverypatientwithpancreaticcancerreceiveperioperativeneoadjuvanttherapy AT helmutfriess shouldeverypatientwithpancreaticcancerreceiveperioperativeneoadjuvanttherapy AT jorgkleeff shouldeverypatientwithpancreaticcancerreceiveperioperativeneoadjuvanttherapy |